scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1035395995 |
P356 | DOI | 10.1038/NRCLINONC.2014.44 |
P8608 | Fatcat ID | release_2xyxdezuljexrdlxfsafj2yidm |
P698 | PubMed publication ID | 24751803 |
P5875 | ResearchGate publication ID | 261769990 |
P50 | author | Andrew Vickers | Q20055453 |
Matthew R Sydes | Q44571830 | ||
Clare Relton | Q48342161 | ||
Tom Leslie | Q55644865 | ||
Mark Emberton | Q63968187 | ||
P2093 | author name string | Timothy Wilt | |
Chris Parker | |||
Hashim U Ahmed | |||
Richard Stephens | |||
Jan van der Meulen | |||
Richard Kaplan | |||
Rakesh Heer | |||
David Bottomley | |||
Viktor Berge | |||
William Cross | |||
Lindsay Turnbull | |||
Prostate Cancer RCT Consensus Group | |||
P2860 | cites work | Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 | Q24656098 |
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel | Q27006744 | ||
Increasing value and reducing waste in biomedical research regulation and management | Q28657841 | ||
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study | Q30514532 | ||
Long-term functional outcomes after treatment for localized prostate cancer | Q30542816 | ||
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer | Q33318333 | ||
Image guided photothermal focal therapy for localized prostate cancer: phase I trial | Q33493721 | ||
??? | Q56773413 | ||
Correlation of magnetic resonance imaging tumor volume with histopathology | Q33773599 | ||
Challenges in evaluating surgical innovation | Q33793659 | ||
Few patients with prostate cancer are willing to be randomised to treatment | Q33796146 | ||
South Yorkshire Cohort: a 'cohort trials facility' study of health and weight - protocol for the recruitment phase. | Q33990868 | ||
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force | Q34044753 | ||
The role of focal therapy in the management of localised prostate cancer: a systematic review | Q34266167 | ||
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management | Q34380870 | ||
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? | Q34463984 | ||
Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be diffic | Q34938393 | ||
Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy | Q35819260 | ||
Radical prostatectomy versus observation for localized prostate cancer | Q36194308 | ||
Developing core outcome sets for clinical trials: issues to consider | Q36320178 | ||
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device | Q36579232 | ||
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer | Q36928846 | ||
Will focal therapy become a standard of care for men with localized prostate cancer? | Q36983662 | ||
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer | Q37254919 | ||
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy | Q37421874 | ||
New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). | Q37586400 | ||
Prostate cancer screening and the management of clinically localized disease | Q37609671 | ||
Pathology of prostate cancer and focal therapy ('male lumpectomy'). | Q37665791 | ||
Tumor focality in prostate cancer: implications for focal therapy | Q37813395 | ||
A biomedical engineering approach to mitigate the errors of prostate biopsy | Q37981828 | ||
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review | Q38022388 | ||
MR imaging-guided focal laser ablation for prostate cancer: phase I trial | Q38084585 | ||
Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard | Q38097009 | ||
Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study | Q38098361 | ||
MRI-targeted prostate biopsy: a review of technique and results | Q38141793 | ||
SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer. | Q39390819 | ||
The PICTURE study -- prostate imaging (multi-parametric MRI and Prostate HistoScanning™) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation | Q39464626 | ||
Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting | Q39477975 | ||
Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series | Q39672788 | ||
Southwest Oncology Group strategies in prostatic carcinoma | Q40527704 | ||
Randomised consent designs in cancer clinical trials | Q40945544 | ||
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens | Q43196725 | ||
A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial | Q43493324 | ||
A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression | Q43861193 | ||
Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry | Q44321478 | ||
Interpreting composite outcomes in trials. | Q44590878 | ||
Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. | Q45905031 | ||
Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. | Q45937049 | ||
Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop | Q46437041 | ||
Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. | Q46663012 | ||
Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial | Q48730138 | ||
A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes | Q49074752 | ||
Focal therapy for localized prostate cancer: a phase I/II trial | Q50246484 | ||
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. | Q50904451 | ||
Incidence of bone metastases in breast cancer patients in the United Kingdom: results of a multi-database linkage study using the general practice research database. | Q51255912 | ||
Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design | Q56780191 | ||
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial | Q56786889 | ||
Radical prostatectomy versus watchful waiting in early prostate cancer | Q57137210 | ||
Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial | Q60716163 | ||
Dynamic Contrast-enhanced–magnetic Resonance Imaging Evaluation of Intraprostatic Prostate Cancer: Correlation with Radical Prostatectomy Specimens | Q63966229 | ||
Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer | Q80501175 | ||
Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry | Q82246523 | ||
Driving up the quality and relevance of research through the use of agreed core outcomes | Q83374039 | ||
Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens | Q83875358 | ||
Prostate biopsy in selecting candidates for hemiablative focal therapy | Q84008631 | ||
Characterizing clinically significant prostate cancer using template prostate mapping biopsy | Q84378694 | ||
Prostate cancer--uncertainty and a way forward | Q84585046 | ||
The index lesion and the origin of prostate cancer | Q84761775 | ||
A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer | Q84950601 | ||
Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer | Q85898760 | ||
P2507 | corrigendum / erratum | Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer? | Q50141300 |
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
P304 | page(s) | 482-491 | |
P577 | publication date | 2014-04-22 | |
P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
P1476 | title | Can we deliver randomized trials of focal therapy in prostate cancer? | |
P478 | volume | 11 |
Q58794132 | A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer |
Q30367832 | Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves |
Q50141300 | Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer? |
Q38436625 | Current trends and new frontiers in focal therapy for localized prostate cancer |
Q36049690 | Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States |
Q50138465 | Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome |
Q40308955 | Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer |
Q30240753 | Focal therapy as primary treatment for localized prostate cancer: definition, needs and future |
Q50241890 | Focal therapy for prostate cancer: German version |
Q41689116 | Focal therapy for prostate cancer: the technical challenges. |
Q57297211 | Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey |
Q35540067 | Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting |
Q89059998 | Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer |
Q36231929 | Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial |
Q88209404 | Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy |
Q48302699 | Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop |
Q89845717 | Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results |
Q85208632 | Re: Jarow et al.: Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop (Urology 2014;83:975-979) |
Q40875442 | Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers |
Q38668993 | The challenging landscape of medical device approval in localized prostate cancer |
Q57112886 | Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement |
Q50141300 | Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer? | main subject | P921 |
Search more.